74 patents
Page 4 of 4
Utility
PPARy AGONIST FOR TREATMENT OF HUNTINGTON'S DISEASE
20 Nov 19
Methods of treatment of Huntington's disease or its symptoms, with PPARγ agonists, and in particular, the compound of formula (I) known as INT131:
Barbara Finck, Lawrence Steinman
Filed: 17 Jan 18
Utility
Etanercept Formulations Stabilized with Sodium Chloride
13 Nov 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark MANNING, Brian MURPHY
Filed: 27 Jun 19
Utility
Etanercept Formulations Stabilized with Sodium Chloride
6 Nov 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark MANNING, Brian MURPHY
Filed: 25 Jun 19
Utility
Etanercept Formulations Stabilized with Meglumine
30 Oct 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark MANNING, Brian MURPHY
Filed: 24 Jun 19
Utility
Correctly Folded Etanercept In High Purity and Excellent Yield
30 Oct 19
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu ARAKAWA, Douglas FARRAR
Filed: 16 Jun 19
Utility
Etanercept Formulations Stabilized with Sodium Chloride
16 Oct 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark MANNING, Brian MURPHY
Filed: 25 Jun 19
Utility
Etanercept Formulations Stabilized with Sodium Chloride
16 Oct 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark MANNING, Brian Murphy
Filed: 25 Jun 19
Utility
Etanercept Formulations Stabilized with Sodium Chloride
16 Oct 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark MANNING, Brian Murphy
Filed: 26 Jun 19
Utility
Methods for making recombinant proteins
7 Oct 19
The present invention provides methods and compositions for making proteins, preferably antibodies, more preferably anti-tumor necrosis factor alpha antibodies, and most preferably adalimumab.
Elzbieta Wiktoria Puchacz
Filed: 3 Sep 15
Utility
Correctly Folded Etanercept In High Purity and Excellent Yield
2 Oct 19
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu ARAKAWA, Douglas FARRAR
Filed: 16 Jun 19
Utility
Correctly Folded Etanercept In High Purity and Excellent Yield
2 Oct 19
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu ARAKAWA, Douglas FARRAR
Filed: 16 Jun 19
Utility
Correctly Folded Etanercept In High Purity and Excellent Yield
2 Oct 19
A mixed mode chromatography method for separating correctly folded from incorrectly folded conformations of a given protein is provided.
Tsutomu ARAKAWA, Douglas FARRAR
Filed: 16 Jun 19
Utility
Methods of Treating Subjects with an Elevated Neurofilament Light Chain Level
2 Oct 19
Provided herein are methods of treating a subject that include selecting a subject having an elevated level of neurofilament light chain protein in a sample including cerebrospinal fluid, blood, serum, or plasma obtained from the subject, as compared to a reference level of neurofilament light chain protein, and administering a pharmaceutical composition including a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, prodrug, or isomer thereof, to the selected subject.
Sarita K. Jain
Filed: 31 Mar 19
Utility
Method of Reducing Formation of Etanercept Aggregates or Fragments
2 Oct 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 13 Jun 19